

**Efficacy and safety of combination therapy with low dose rivaroxaban in patients with cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials**


Tommaso Bucci, Francesco Del Sole, Danilo Menichelli, Gioacchino Galardo, Flavio Giuseppe Biccirè,  
Alessio Farcomeni, Gregory Y.H. Lip, Pasquale Pignatelli, Daniele Pastori

Supplementary materials


**Supplementary Table S1.** Literature online search strategies.

<b>Database</b>	<b>Search strategy</b>
PubMed	'rivaroxaban' AND 'coronary artery disease' OR 'peripheral artery disease'
Embase	'rivaroxaban' /exp AND 'coronary artery disease' OR 'peripheral artery disease' /exp
Web of Science	ALL= rivaroxaban ' AND ALL= 'coronary artery disease' OR 'peripheral artery disease'


Supplementary Figure S1. Funnel plots for safety endpoints.






Any bleeding




Fatal bleeding




ICH




Supplementary Figure S2. Funnel plots for efficacy endpoints.






All cause mortality




CV mortality




Myocardial Infarction



Supplementary Figure S3. Efficacy endpoints in patients with coronary artery disease.




Supplementary Figure S4. Safety endpoints in patients with coronary artery disease.




Supplementary Figure S5. Safety and efficacy endpoints in patients with peripheral artery disease.


### Cardiovascular events




### Cardiovascular death




### Stroke



### All-cause mortality



### Myocardial Infarction



### Major bleeding

